. 2020 Aug 29;9(9):1992. doi: 10.3390/cells9091992

Table 3.

SS transcriptomic profiling studies included in Figure 3.

Meta-Analysis Study	Sézary Patients	Healthy Donors	BID	Technology
Moerman-Herzog et al. [22]	n = 3 CD3⁺CD4⁺CD45RO⁺	n = 3 CD3⁺CD4⁺CD45RO⁺	n.a.	microarray
Prior Study	Sézary Patients	Healthy Donors	BID	Technology
Fanok et al. [73]	n = 8 CD3⁺CD4⁺CD7⁻ and/or CD3⁺CD4⁺CD26⁻	n =4 CD3⁺CD4⁺CD45RO⁺	n.a.	RNAseq
Wang et al. [68]	n = 22 CD3⁺CD4⁺	n = 5 CD3⁺CD4⁺	n.a.	RNAseq
Wysocka et al. [78]	n = 6 CD3⁺CD4⁺	n = 3 CD3⁺CD4⁺	n.a.	microarray
Wang et al. [72]	n = 6 CD3⁺CD4⁺CD7-	n = 9 CD3⁺CD4⁺	n.a.	microarray
Booken et al. [16]	n = 10 PBMC	n =10 PBMC	n.a.	microarray
Hahtola et al. [17]	n = 4 PBMC	n = 5 PBMC	n.a.	microarray
van Doorn et al. [14]	n = 10 CD3⁺CD4⁺	n = 3 CD3⁺CD4⁺	n = 5 CD3⁺CD4⁺	microarray
Kari et al. [71]	n = 18 >60% CD4⁺	n = 12 Th2-skewed PBMC	n.a.	microarray
Prior Study	Sézary Malignant Cells	Patient-Matched Non-Malignant Cells	BID	Technology
Borcherding et al. [74]	n = 1 CD3⁺CD4⁺CD5^brightSSC^hi	n = 1 CD3⁺CD4⁺CD5^intSSC^int	n.a.	scRNAseq
Lee et al. [75]	n = 3 CD3⁺CD4⁺Vβ⁺	n = 3 CD3⁺CD4⁺Vβ⁻	n.a.	RNAseq

n.a., not applicable; RNAseq, RNA sequencing; scRNAseq, single cell RNAseq.